货号:A533908
同义名:
L-硒甲基硒代半胱氨酸
/ Methylselenocysteine hydrochloride; Se-Methylseleno-L-cysteine hydrochloride
Se-Methylselenocysteine hydrochloride是甲基硒的前体,具有显著的抗癌化学预防和抗氧化活性。该化合物能够诱导细胞凋亡,具有口服生物活性,广泛用于癌症预防和抗氧化剂研究。
HazMat Fee + There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.
| Type | HazMat fee for 500 gram (Estimated) |
| Excepted Quantity | USD 0.00 |
| Limited Quantity | USD 15-60 |
| Inaccessible (Haz class 6.1), Domestic | USD 80+ |
| Inaccessible (Haz class 6.1), International | USD 150+ |
| Accessible (Haz class 3, 4, 5 or 8), Domestic | USD 100+ |
| Accessible (Haz class 3, 4, 5 or 8), International | USD 200+ |


| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 产品名称 | mTOR ↓ ↑ | mTORC1 ↓ ↑ | mTORC2 ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AZD-8055 |
++++
mTOR (full length), IC50: 0.8 nM mTOR (truncated), IC50: 0.13 nM |
99%+ | |||||||||||||||||
| Gedatolisib |
++++
mTOR, IC50: 1.6 nM |
99% | |||||||||||||||||
| GSK1059615 |
++
mTOR, IC50: 12 nM |
98% | |||||||||||||||||
| Vistusertib |
+++
mTOR, IC50: 2.8 nM |
99%+ | |||||||||||||||||
| Torin 1 |
+++
mTOR, IC50: 4.32 nM |
+++
mTORC1, IC50: 2 nM |
++
mTORC2, IC50: 10 nM |
DNA-PK | 99%+ | ||||||||||||||
| Dactolisib |
+++
mTOR (p70S6K), IC50: 6 nM |
98+% | |||||||||||||||||
| PI-103 |
+
mTOR, IC50: 30 nM |
99%+ | |||||||||||||||||
| WAY-600 |
++
mTOR, IC50: 9 nM |
99% | |||||||||||||||||
| Voxtalisib |
+
mTOR, IC50: 157 nM |
99%+ | |||||||||||||||||
| PF-04691502 |
++
mTOR, Ki: 16 nM |
98+% | |||||||||||||||||
| Onatasertib |
++
mTOR, IC50: 16 nM |
DNA-PK | 99%+ | ||||||||||||||||
| Chrysophanol | ✔ | EGFR | 98% | ||||||||||||||||
| Samotolisib | ✔ | DNA-PK | 99%+ | ||||||||||||||||
| Torkinib |
+++
mTOR, IC50: 8 nM |
PDGFR,DNA-PK | 99%+ | ||||||||||||||||
| Everolimus | 99%+ | ||||||||||||||||||
| WYE-354 |
+++
mTOR, IC50: 5 nM |
98% | |||||||||||||||||
| Tacrolimus | ✔ | 98% | |||||||||||||||||
| PP121 |
++
mTOR, IC50: 13 nM |
PDGFR,VEGFR | 99%+ | ||||||||||||||||
| Torin 2 |
++++
mTOR, IC50: 0.25 nM |
DNA-PK | 99%+ | ||||||||||||||||
| Rapamycin |
++++
mTOR, IC50: ~0.1 nM |
98% | |||||||||||||||||
| GDC-0349 |
+++
mTOR, Ki: 3.8 nM |
98% | |||||||||||||||||
| XL388 |
++
mTOR, IC50: 9.9 nM |
+++
mTORC1, IC50: 8 nM |
+
mTORC2, IC50: 166 nM |
99%+ | |||||||||||||||
| WYE-687 |
+++
mTOR, IC50: 7 nM |
98% | |||||||||||||||||
| Apitolisib |
+
mTOR, Ki app: 17 nM |
98%+ | |||||||||||||||||
| WYE-132 |
++++
mTOR, IC50: 0.19 nM |
99%+ | |||||||||||||||||
| Sapanisertib |
++++
mTOR, Ki: 1.4 nM |
99%+ | |||||||||||||||||
| BGT226 maleate | ✔ | 99%+ | |||||||||||||||||
| ETP-46464 |
++++
mTOR, IC50: 0.6 nM |
DNA-PK | 98% | ||||||||||||||||
| PI3K-IN-1 |
+
mTOR, IC50: 157 nM |
98+% | |||||||||||||||||
| Zotarolimus |
+++
FKBP-12, IC50: 2.8 nM |
98% | |||||||||||||||||
| OSI-027 |
+++
mTOR, IC50: 4 nM |
+
mTORC1, IC50: 22 nM |
+
mTORC2, IC50: 65 nM |
99%+ | |||||||||||||||
| Ridaforolimus |
++++
mTOR, IC50: 0.2 nM |
99%+ | |||||||||||||||||
| Temsirolimus |
+
mTOR, IC50: 1.76 μM |
95% | |||||||||||||||||
| CZ415 |
++
mTOR, pIC50: 8.07 |
99%+ | |||||||||||||||||
| SF2523 |
+
mTOR, IC50: 280 nM |
DNA-PK | 99%+ | ||||||||||||||||
| KU-0063794 |
++
mTORC1, IC50: ~10 nM |
++
mTORC2, IC50: ~10 nM |
99%+ | ||||||||||||||||
| Omipalisib |
++++
mTORC1, Ki: 0.18 nM |
++++
mTORC2, Ki: 0.3 nM |
99%+ | ||||||||||||||||
| Palomid 529 | ✔ | 99%+ | |||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| Concentration | Treated Time | Description | References | |
| 293T embryonic kidney cells | 50-200 µM | 24-48 hours | No cytotoxicity was observed | Cell Prolif. 2021 May;54(5):e13038 |
| L6 myoblast cells | 50-200 µM | 24-48 hours | No cytotoxicity was observed | Cell Prolif. 2021 May;54(5):e13038 |
| Hepa1-6 hepatoma cells | 50-200 µM | 24-48 hours | Not sensitive to SeMC treatment | Cell Prolif. 2021 May;54(5):e13038 |
| CT26 colon carcinoma cells | 50-200 µM | 24-48 hours | Not sensitive to SeMC treatment | Cell Prolif. 2021 May;54(5):e13038 |
| 4T1 mammary carcinoma cells | 50-200 µM | 24-48 hours | Not sensitive to SeMC treatment | Cell Prolif. 2021 May;54(5):e13038 |
| TM6 mouse mammary epithelial tumor cells | 100 µM | 16 and 24 hours | To study the effect of MSC on PI3-K activity, results showed that MSC reduced PI3-K activity by 73% and 84% at 16 and 24 hours, respectively. | Breast Cancer Res. 2005;7(5):R699-707 |
| TM6 mouse mammary epithelial tumor cells | 50 µM | 16 hours | To study the effect of MSC on DNA synthesis, results showed that MSC inhibited 33% of DNA synthesis at 16 hours. | Breast Cancer Res. 2005;7(5):R699-707 |
| Human neuroblastoma SH-SY5Y cells | 1 µM | 24 hours | To investigate the effect of MSC on apoptosis in Clu-knockdown SH-SY5Y cells. Results showed that 1 μM MSC could reverse the decrease in antioxidative capacity, Bcl-2/Bax ratio, and increase in caspase-8 activity caused by Clu-knockdown, thereby inhibiting apoptosis and maintaining cell viability. | Int J Mol Sci. 2014 Nov 18;15(11):21331-47 |
| Mouse neuroblastoma N2a cells | 1 µM | 24 hours | To investigate the effect of MSC on apoptosis in Clu-knockdown N2a cells. Results showed that 1 μM MSC could reverse the decrease in antioxidative capacity, Bcl-2/Bax ratio, and increase in caspase-8 activity caused by Clu-knockdown, thereby inhibiting apoptosis and maintaining cell viability. | Int J Mol Sci. 2014 Nov 18;15(11):21331-47 |
| A549 lung adenocarcinoma cells | 50-200 µM | 24-48 hours | SeMC inhibited A549 cell growth in a dose-dependent manner | Cell Prolif. 2021 May;54(5):e13038 |
| Primary human hepatocytes | 1218 ± 364 µM (IC50) | 72 hours | Evaluate the cytotoxicity of MSC on primary human hepatocytes, the IC50 value was 1218 ± 364 µM | Antioxidants (Basel). 2021 Jul 7;10(7):1094 |
| Huh7 cells | 1294 ± 336 µM (IC50) | 72 hours | Evaluate the cytotoxicity of MSC on HCC cell lines, the IC50 value of Huh7 cells was 1294 ± 336 µM | Antioxidants (Basel). 2021 Jul 7;10(7):1094 |
| Hep3B cells | 1875 ± 171 µM (IC50) | 72 hours | Evaluate the cytotoxicity of MSC on HCC cell lines, the IC50 value of Hep3B cells was 1875 ± 171 µM | Antioxidants (Basel). 2021 Jul 7;10(7):1094 |
| HEPG2 cells | 1152 ± 188 µM (IC50) | 72 hours | Evaluate the cytotoxicity of MSC on HCC cell lines, the IC50 value of HEPG2 cells was 1152 ± 188 µM | Antioxidants (Basel). 2021 Jul 7;10(7):1094 |
| Administration | Dosage | Frequency | Description | References | ||
| Nude mice | FaDu and A253 head and neck squamous cell carcinoma xenograft models | Oral | 0.2 mg/mouse/day | Daily administration for 7 days (before chemotherapy) and 7 days (after chemotherapy) | Se-methylselenocysteine significantly protected against organ-specific toxicity induced by lethal doses of cyclophosphamide, cisplatin, oxaliplatin, and irinotecan, including diarrhoea, stomatitis, alopecia, bladder, kidney, and bone marrow toxicities. Protection from lethal toxicity by MSC was associated with enhanced antitumour activity in rats bearing advanced Ward colorectal carcinoma and in nude mice bearing human squamous cell carcinoma of the head and neck, FaDu, and A253xenografts. | Antioxidants (Basel). 2019 Jul 5;8(7):207 |
| Fischer 344/N rats | Ward colorectal carcinoma model | Oral | 0.25 to 1.25 mg/rat/day | Daily administration for 14 days (before chemotherapy) and 7 days (after chemotherapy) | Se-methylselenocysteine significantly protected against organ-specific toxicity induced by lethal doses of cyclophosphamide, cisplatin, oxaliplatin, and irinotecan, including diarrhoea, stomatitis, alopecia, bladder, kidney, and bone marrow toxicities. Protection from lethal toxicity by MSC was associated with enhanced antitumour activity in rats bearing advanced Ward colorectal carcinoma and in nude mice bearing human squamous cell carcinoma of the head and neck, FaDu, and A253xenografts. | Antioxidants (Basel). 2019 Jul 5;8(7):207 |
| BALB/c nude mice | A549 lung carcinoma xenograft model | Intratumoral injection | 2 mg/kg SeMC and 2 mg/kg EBN | Every four days from day 3 to day 27 | SeMC/EBN@Gel significantly inhibited tumor growth | Cell Prolif. 2021 May;54(5):e13038 |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
4.58mL 0.92mL 0.46mL |
22.88mL 4.58mL 2.29mL |
45.76mL 9.15mL 4.58mL |
|
| CAS号 | 863394-07-4 |
| 分子式 | C4H10ClNO2Se |
| 分子量 | 218.54 |
| SMILES Code | O=C(O)[C@@H](N)C[Se]C.[H]Cl |
| MDL No. | MFCD03412450 |
| 别名 | L-硒甲基硒代半胱氨酸 ;Methylselenocysteine hydrochloride; Se-Methylseleno-L-cysteine hydrochloride; Se-methyl-L-Selenocysteine; Se-MeSeCys; Methylselenocysteine; Se-Methylselenocysteine (hydrochloride) |
| 运输 | 蓝冰 |
| InChI Key | JMPVTFHGWJDSDV-DFWYDOINSA-N |
| Pubchem ID | 11957622 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Inert atmosphere, store in freezer, under -20°C |
沪公网安备 31011702889066号
沪ICP备2024050318号-1